Skip to main content
. 2017 Oct 2;214(10):2967–2983. doi: 10.1084/jem.20161721

Figure 6.

Figure 6.

Human TAT–BCL-XL protein protects human CD34+ cells under conditions of stress. (A) Fresh cord blood derived CD34+ cells were treated with dextran sulfate (100 μg/ml) for 30 min and TAT–BCL-XL (1.5 μM) for 2 h in serum-free medium. At day 2, TAT–BCL-XL–positive cells were determined by intracellular flow cytometry using an anti–BCL-XL antibody. (B) TAT–BCL-XL–treated or untreated CD34+ cells were cultured in the presence or absence of rhSCF, rhFlt3L (100 ng/ml each), rhTPO (50 ng/ml), and rhIL3 (20 ng/ml) for 6 d. At days 2, 4, and 6, percentage of TAT–BCL-XL–positive cells was determined by flow cytometry. Bars represent x-fold accumulation = (%TAT–BCL-XL+ in absence of cytokines)/(%TAT–BCL-XL+ cultured with cytokines). (C) At days 2, 4, and 6, apoptosis was determined in the different cell populations (untreated, TAT–BCL-XL–negative, and TAT–BCL-XL–positive cells) by flow cytometry, and the percent specific apoptosis was determined. Bars represent means of n = 5 from four independent experiments ± SEM. Significant p-values (Mann–Whitney test): (C) P = 0.02 for TAT–BCL-XL negative vs. TAT–BCL-XL positive on day 4; P = 0.04 for untreated vs. TAT–BCL-XL positive and TAT–BCL-XL negative vs. TAT–BCL-XL positive.